LeonaBio (LONA) director awarded options on 28,000 shares at $9.54

Rhea-AI Filing Summary

LeonaBio, Inc. director Joseph Edelman received a grant of stock options covering 28,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036. The award vests monthly over 24 months, so Edelman earns portions of the grant gradually as he continues to serve as a service provider. Following this grant, he holds stock options for 28,000 underlying shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider EDELMAN JOSEPH

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	28,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 28,000 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 28,000 shares Exercise price: $9.54 per share Expiration date: April 8, 2036 +2 more

5 metrics

Option grant size 28,000 shares Stock options granted to director on April 9, 2026

Exercise price $9.54 per share Strike price for the stock option grant

Expiration date April 8, 2036 Option term end for director grant

Vesting schedule 24 monthly installments Options vest monthly over 24 months from grant date

Options held after grant 28,000 shares Total underlying shares in options following this transaction

Key Terms

Stock Option (Right to Buy), vesting, 2026 Equity Incentive Plan, Grant, award, or other acquisition

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

vesting financial

"scheduled to vest monthly over a term of 24 months"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

2026 Equity Incentive Plan financial

"as defined in the Issuer's 2026 Equity Incentive Plan"

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

EDELMAN JOSEPH

(Last) (First) (Middle)

C/O LEONABIO, INC.

18706 NORTH CREEK PARKWAY, SUITE 104

(Street)

BOTHELL WASHINGTON 98011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LeonaBio, Inc. [ LONA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.54	04/09/2026		A		28,000		(1)	04/08/2036	Common Stock	28,000	$0	28,000	D

Explanation of Responses:

1. The shares subject to the option shall be scheduled to vest monthly over a term of 24 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates.

	/s/ Mark Worthington, Attorney in fact for Joseph Edelman	04/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did LeonaBio (LONA) director Joseph Edelman report in this Form 4?

Director Joseph Edelman reported receiving a stock option grant for 28,000 shares of LeonaBio common stock. The options were awarded at a $9.54 exercise price and give him the right to buy shares if he meets the vesting and timing conditions.

What are the key terms of Joseph Edelman’s LeonaBio stock option grant?

Edelman’s grant covers 28,000 shares at a $9.54 exercise price and expires April 8, 2036. The options vest monthly over 24 months, meaning portions become exercisable each month as long as he remains a service provider.

How do Joseph Edelman’s LeonaBio options vest over time?

The 28,000 LeonaBio options vest in equal monthly installments over 24 months from the grant date. Each month, another fraction becomes exercisable, provided Edelman continues as a service provider under the company’s 2026 Equity Incentive Plan.

Did Joseph Edelman buy or sell any LeonaBio common stock in this filing?

No open-market buys or sells were reported. The Form 4 shows a grant of stock options, classified as an acquisition under code A, rather than a market purchase or sale of existing LeonaBio common shares.

How many LeonaBio shares are covered by Joseph Edelman’s options after this transaction?

After this grant, Edelman holds stock options covering 28,000 shares of LeonaBio common stock directly. These options may be exercised at $9.54 per share once vested and before their April 8, 2036 expiration.